Cytori Therapeutics specializes in developing cell therapies using ADRCs obtained from human adipose tissue. Their lead product candidate is Cytori Cell Therapy for scleroderma-associated hand dysfunction, which is currently in phase III trials. They are also studying the therapy for thermal burns, hip osteonecrosis, knee osteoarthritis, and stress urinary incontinence in the US and Japan. The company has partnerships with Bimini Technologies and Cytori KK, and their technologies are in the process of FDA approval.